Bristol-Myers Squibb Company (BMY)

54.59
0.31 0.57
NYSE : Health Care
Prev Close 54.28
Open 54.28
Day Low/High 54.08 / 54.72
52 Wk Low/High 46.01 / 77.12
Volume 9.71M
Avg Volume 12.10M
Exchange NYSE
Shares Outstanding 1.67B
Market Cap 90.71B
EPS 2.70
P/E Ratio 20.48
Div & Yield 1.56 (2.90%)

Latest News

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

U.S. Steel, Universal Display, Bristol-Myers Squibb: 'Mad Money' Lightning Round

U.S. Steel, Universal Display, Bristol-Myers Squibb: 'Mad Money' Lightning Round

Jim Cramer is bullish on United States Steel and Universal Display, less so with Arconic and Himax Technologies.

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Investors should keep an eye on interest rates and oil, but remember next week is still a week of big earnings reports, says Jim Cramer.

Here's How the Tom Price Stock Portfolio Is Performing Now That He Is Confirmed

Here's How the Tom Price Stock Portfolio Is Performing Now That He Is Confirmed

Tom Price will now head the Department of Health and Human Services.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Bristol-Myers Squibb To Take Part In Leerink 6th Annual Global Health Care Conference

Bristol-Myers Squibb To Take Part In Leerink 6th Annual Global Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Leerink Annual Global Health Care Conference on Wednesday, February 15, 2017, in New York.

Lower Valuations Have Merck Looking 'Very Hard' at M&A Options

Lower Valuations Have Merck Looking 'Very Hard' at M&A Options

On an earnings call, Merck CEO Kenneth Frazier said the company will continue to seek opportunities with a particular focus on augmenting its early- to mid-stage pipeline.

Cancer Survivors Need More Efficient Integrated Long-Term Care And Stronger Policies Across Healthcare, Advocacy And The Workplace, New Research Concludes

Cancer Survivors Need More Efficient Integrated Long-Term Care And Stronger Policies Across Healthcare, Advocacy And The Workplace, New Research Concludes

As more patients are living longer with cancer, multi-stakeholder-driven changes are required to improve integrated, or coordinated, care that addresses the range of their long-term needs, according to a new Bristol-Myers...

Merck Posts In-Line Fourth-Quarter Earnings, Issues Cautious 2017 Sales Outlook

Merck Posts In-Line Fourth-Quarter Earnings, Issues Cautious 2017 Sales Outlook

Merck posts fourth-quarter earnings largely in line with estimates but issues a cautious outlook for the year.

Spotlight on Keytruda as Merck Prepares to Unveil Fourth-Quarter Results

Spotlight on Keytruda as Merck Prepares to Unveil Fourth-Quarter Results

Analysts have forecast fourth-quarter sales of $470 million for Merck's cancer drug Keytruda.

Bristol-Myers Squibb Announces European Patent Office Decision On Sprycel

Bristol-Myers Squibb Announces European Patent Office Decision On Sprycel

Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Patent Office (EPO) upheld a decision with regard to European Patent No.

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Two industries should largely be avoided under this administration: pharma and retail.

All Eyes on Growth Plans as Pfizer Gears Up for Fourth Quarter Earnings

All Eyes on Growth Plans as Pfizer Gears Up for Fourth Quarter Earnings

Investors will be listening for details around competition facing key products and plans for capital deployment.

The Selling Isn't That Scary

Index says selling isn't heavy enough to fuss over. Yet.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Allergan, Starbucks, Citigroup: Doug Kass' Views

Allergan, Starbucks, Citigroup: Doug Kass' Views

Doug Kass shares his thoughts on Starbucks, and discusses what, if anything, Dow 20,000 means.

Sell Calls for Bristol-Myers to Limit Risk on Volatility

Sell Calls for Bristol-Myers to Limit Risk on Volatility

Selling a call on Bristol-Myers Squibb would help investors limit their risk as the pharmaceutical company's volatility increased recently.

After Setback, Bristol-Myers Remains Committed to Developing Opdivo-Yervoy Combo

After Setback, Bristol-Myers Remains Committed to Developing Opdivo-Yervoy Combo

On an earnings call this morning, Bristol-Myers CEO Giovanni Caforio noted that the company has a broad front-line lung cancer program.

Dow Scores Another Record but S&P 500, Nasdaq Decline

Dow Scores Another Record but S&P 500, Nasdaq Decline

The Dow Jones Industrial Average scores a record close for its second day in a row, benefiting from a small bump that cemented its position above 20,000.

Dow Set for a Fresh Record as DuPont Provides a Bump

Dow Set for a Fresh Record as DuPont Provides a Bump

The Dow Jones Industrial Average is on track to squeeze out another record close, its second in a row, in a mixed session.

Jim Cramer: Bristol-Myers Needs to Slim Down

Jim Cramer: Bristol-Myers Needs to Slim Down

Bristol-Myers Squibb needs to reorganize itself in what is now a challenging environment, says Jim Cramer.

Stocks Hold Mixed as Record-Breaking Rally Pauses

Stocks Hold Mixed as Record-Breaking Rally Pauses

Stocks hold mixed on Thursday as markets run out of steam to push a record-breaking rally into day two.

Stock Futures Turn Mixed as Wall Street Pauses After Historic Rally

Stock Futures Turn Mixed as Wall Street Pauses After Historic Rally

Stock futures turn mixed on Thursday as investors take pause after Wednesday's history-making rally.

As the Trump Rally Resumes, Buy This Battered Health Sector Blue-Chip

As the Trump Rally Resumes, Buy This Battered Health Sector Blue-Chip

Stocks hit record highs this week, indicating that the postelection surge still has momentum. Bargains are hard to find, but this health giant is a smart value play now.

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

McKesson, Bristol-Myers and Varian were having a busy morning.